Vaccine Development Technology Articles & Analysis
13 news found
Dedicated to the research of new immunotherapeutic vaccines in oncology and prophylactic vaccines for contagious diseases, the aim of the joint Institut Pasteur – Oncovita laboratory is to design and develop vaccine candidates through to proof of concept in humans. Oncovita and the Institut Pasteur have already been ...
ByOncoVITA
About PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] VBI’s hepatitis B vaccine is the only 3-antigen hepatitis B vaccine, comprised of the three hepatitis B surface antigens of the hepatitis B virus – S, pre-S1, and pre-S2. ...
About Valneva SE Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding ...
CD BioGlyco, a biotechnology company specialized in the field of glycobiology, has developed a series of advanced vaccine development platforms by integrating various advanced technologies to promote the development of glycol-based vaccines. ...
Dillman will be responsible for leading VBI’s commercial strategy, sales, and sales operations, including the commercialization of VBI’s 3-Antigen Hepatitis B Vaccine (HBV), PreHevbrio™ [Hepatitis B Vaccine (Recombinant)]. ...
“In the PROTECT study, more adults were protected with VBI’s 3-antigen vaccine than with the single-antigen vaccine, and in this follow-up analysis we continued to see the benefit of the 3-antigen vaccine,” said Francisco Diaz-Mitoma, M.D., Ph.D., VBI’s Chief Medical Officer. ...
FDA Orphan Drug Designation reflects urgent need for new therapies for glioblastoma (GBM) patients Next steps for development of VBI-1901 : Q3 2022: Expected initiation of randomized, controlled clinical study in recurrent GBM patients with potential to support accelerated approval application Q4 2022: Expected initiation of randomized, controlled evaluation in primary GBM ...
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, VBI’s President and CEO, will participate in an analyst-led fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022. ...
We remain in close discussion with our study investigators and scientific advisors as we move toward the next stages of development in both the recurrent and frontline GBM settings, and look forward to advancing this development program as diligently as ...
PreHevbri is the only approved 3-antigen hepatitis B vaccine for adults in the United Kingdom Approval follows the European Commission’s marketing authorisation, granted in April 2022 VBI Vaccines Inc. ...
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that an abstract highlighting long-term durability of immune response data following vaccination with VBI’s 3-antigen hepatitis B (HBV) vaccine has been accepted for oral ...
Location: Congress Center Basel – Basel, Switzerland Presentation: Late-stage clinical development of a personalized vaccine platform technology for cancer and COVID-19 When: Wednesday, November 10, 11:50 AM CEST Location: Congress Center Basel – Basel, ...
The technology can be used for an exceptionally broad range of applications in vaccine development and has established proof of concept data in a viral, bacterial, parasitic diseases and chronic diseases and cancer. SpyBiotech has exclusive rights from the University of Oxford to apply, commercialise and sub-license the “plug and ...